Evidence map›Paper›PMID 42099338›Full record

ArticleCureus2026

Dapagliflozin-Based Therapies in Patients With Type 2 Diabetes Mellitus in an Outpatient Real-World Setting Across India: The DAPATURN Study.

Rajeev Chawla, Sabeer T K, K P Singh, Ashwani Mehta, Mounam Chattopadhyay, Kaushik M Rakshit, Nikhil Motiramani, Rajeev Philip, Amber C Shinde, Sowmiya M K and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Rajeev ChawlaDiabetology, North Delhi Diabetes Centre, New Delhi, IND.
Sabeer T KDiabetes and Endocrinology, Diacare Centre for Diabetes and Endocrinology, Kannur, IND.
K P SinghDiabetes and Endocrinology, Fortis Hospital, Mohali, IND.
Ashwani MehtaCardiology, Sir Ganga Ram Hospital, New Delhi, IND.
Mounam ChattopadhyayDiabetes and Endocrinology, Techno India Dama Hospital, Kolkata, IND.
Kaushik M RakshitCardiology, Shaw's Diagnostic, Kolkata, IND.
Nikhil MotiramaniMedicine, Shri Balaji Institute of Medical Sciences, Raipur, IND.
Rajeev PhilipEndocrinology, Pushpagiri Institute of Medical Science and Research Centre, Thiruvalla, IND.
Amber C ShindeGeneral Medicine, Health First Clinic, Mumbai, IND.
Sowmiya M KMedical Services, Medical Affairs Division, Lupin Limited, Mumbai, IND.
Santosh RevenkarMedical Services, Medical Affairs Division, Lupin Limited, Mumbai, IND.
Kamlesh PatelMedical Services, Medical Affairs Division, Lupin Limited, Mumbai, IND.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimDetermination of usage patterns and clinical profile of patients receiving dapagliflozin and its combinations in outpatient settings across India.

methodsAn observational, cross-sectional study was conducted across 661 sites in four zones of India from March to December 2024. Baseline demographics, comorbidities, and used dapagliflozin formulations (dual or triple fixed-dose combination (FDC)) were recorded to analyze usage patterns.

resultA total of 34,443 patients were enrolled from North (

conclusionsThis study highlights real-world dapagliflozin use in India, showing that dapagliflozin-based FDCs are widely adopted across diverse patient groups.

Indexed as

comorbiditiesdapagliflozinindiasitagliptinusage pattern

Identifiers

PMID42099338
PMCPMC13147304

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.